Breaking News, Collaborations & Alliances

Catalent Provides Clinical Support for COVID-19 Study

Partners with Humanigen for FDA-approved Phase 3 lenzilumab study for COVID-19 patients

By: Contract Pharma

Contract Pharma Staff

Catalent’s clinical partner, Humanigen, has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.   From its Philadelphia, PA facility, Catalent has provided clinical supply support to Humanigen and its partners to accelerate the instigation of this clinical trial.   “We are honored to have supported Humanigen on this important projec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters